Clinical and Financial Outcomes
Quantifiable and measurable patient outcomes are influenced by microbiology procedures. We have designed and implemented strategies that evaluate the benefit of diagnostic/clinical microbiology, particularly recognizing the cost of new microbial-based technologies (MICROBIOLOGY MANAGEMENT BY OUTCOMES). Is there a measurable clinical and economic benefit?
To maximize positive outcomes via early intervention, we are also evaluation computer assisted diagnosis to risk stratify out patients where traditional culture methods are poor predictors. Initially, we focused on fungal infections using MDRA (Multi-disease Risk Assessment-Pfizer Inc.), GIDEON (Global Infectious Disease Epidemiology Network) and Rapid Reporting of AST (Antimicrobial Susceptibility Tests) using VITEK II (bioMerieux).